Skip to main content
. Author manuscript; available in PMC: 2019 Dec 31.
Published in final edited form as: Cell Rep. 2019 Dec 10;29(11):3405–3420.e5. doi: 10.1016/j.celrep.2019.11.008

Figure 7. CD36-Mediated FA Uptake Is Required for HER2-Positive Breast Tumor Cells to Acquire Resistance to HER2 Inhibitors.

Figure 7.

(A) Cells acquire FAs endogenously through FASN and/or exogenously via CD36. HER2 activates FASN by phosphorylation and also by transcriptional induction.

(B) Inhibition of HER2 by lapatinib or trastuzumab results in suppression of FASN activity, leaving CD36 as the major source of FA acquisition.